General
Preferred name
LITHOCHOLIC ACID
Synonyms
3¦Á-Hydroxy-5¦Â-cholanic acid ()
3??-Hydroxy-5??-cholanic acid ()
3??-Hydroxy-5??cholanic acid ()
Bevacizumab + Trastuzumab ()
Lithocholate ()
Litocholic Acid ()
Lithocholic Acid-d4 ()
Lithocholic Acid-d4 MaxSpec? Standard ()
Lithocholic Acid MaxSpec? Standard ()
P&D ID
PD012162
CAS
434-13-9
83701-16-0
Tags
available
drug candidate
Drug indication
Breast cancer
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Cell lines
3
Organisms
1
Compound Sets
20
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugMAP
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Prestwick Chemical Library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
ZINC Tool Compounds
External IDs
53
Properties
(calculated by RDKit )
Molecular Weight
376.3
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
0
cLogP
5.51
TPSA
57.53
Fraction CSP3
0.96
Chiral centers
9.0
Largest ring
6.0
QED
0.68
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Metabolism
Apoptosis
Autophagy
Metabolic Enzyme/Protease
Target
FXR
PXR
VD
GPBAR1, NR1H4, NR1I2, VDR
Endogenous Metabolite
MOA
FXR antagonist, vitamin D receptor agonist
Recommended Cell Concentration
None
Source data